GSK announces US leadership changesGlaxoSmithKline has poached Merck KGaA’s Maya Martinez-Davis to head up its US Pharmaceuticals division as it announces current Share XGSK announces US leadership changeshttps://pharmaphorum.com/news/gsk-announces-us-leadership-changes/
GSK eyeing industry vet Jonathan Symonds as new chair; reportGlaxoSmithKline is reported to have found the person it wants to replace Sir Philip Hampton as its non-executive Share XGSK eyeing industry vet Jonathan Symonds as new chair; reporthttps://pharmaphorum.com/news/gsk-eyeing-industry-vet-jonathan-symonds-as-new-chair-report/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
GSK makes CRISPR play, funding Doudna lab in CaliforniaGlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new Share XGSK makes CRISPR play, funding Doudna lab in Californiahttps://pharmaphorum.com/news/gsk-makes-crispr-play-funding-doudna-lab-in-california/
Novartis builds case for asthma drugs to challenge GSKNovartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take Share XNovartis builds case for asthma drugs to challenge GSKhttps://pharmaphorum.com/news/novartis-asthma-drugs-challenge-gsk/
Trial could unlock asthma use for GSK’s TrelegyGlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple Share XTrial could unlock asthma use for GSK’s Trelegyhttps://pharmaphorum.com/news/trial-could-unlock-asthma-use-for-gsks-trelegy/
Shingles vaccine boosts GSK as generic Advair bitesGSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of Share XShingles vaccine boosts GSK as generic Advair biteshttps://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/
FDA approves first treatment for children with lupusThe US FDA has approved GSK’s Benlysta (belimumab) intravenous infusion for the treatment of children with lupus. While Share XFDA approves first treatment for children with lupushttps://pharmaphorum.com/news/fda-approves-first-treatment-children-lupus/
Fulcrum repurposes failed GSK drug for rare diseaseGSK’s failed cardiovascular drug losmapimod looks like it might get a new lease of life after being picked Share XFulcrum repurposes failed GSK drug for rare diseasehttps://pharmaphorum.com/news/fulcrum-repurposes-failed-gsk-drug-for-rare-disease/
